Medical Marijuana webinar This webinar is titled Marijuana for Medical Purposes Regulation (MMPR) – What Do I Need to Know?, and took place on Thursday, August 20 from1:00pm EDT – 2:00pm EDT. During this webinar we were joined by Kaivan Talachian of CannTrust, Inc. Webinar informationDuring this webinar, attendees will learn about: Marijuana for Medical Purposes Regulations (MMPR) Statistics on cannabis usage and results of the CCSN
Month: August 2015
Health Canada Approves IMBRUVICA? by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia
Ontario patients living with CLL and SLL who are eligible will now have access to IMBRUVICA® under the Exceptional Access Program of the Ontario Drug Benefit Program. Eligibility criteria include those patients who: have CLL/SLL and have received at least one prior therapy to treat CLL/SLL; and, are inappropriate for treatment or retreatment with a fludarabine-based regimen. To determine whether patients qualify for IMBRUVICA® treatment
Xofigo is added to the Liste des médicaments ? Établissements in Quebec
TORONTO, ON, July 27, 2015 – Men in Quebec are one step closer to accessing Xofigo (radium Ra 223 dichloride), for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease, thanks to a recent announcement by the Quebec government. Xofigo will be included on the Quebec Liste des médicaments – Établissements, giving hospitals the ability to provide